Well lets hope the new Abbie drug soon to be approved provides much more realistic pricing. They're never going to make their money back at those prices....Greedy bar stewards might learn something when we are all cured from a much cheaper regime or so I hope!
Cinnamon Girl said
Jun 17, 2014
Thanks for that Lee, and I posted about it in the HCV News section recently...
The decision hasn`t been finalised yet, it`s still in the consultation stage until 4th July, but it looks likely at the moment that Sovaldi will only be made available to people in the most needy categories over here in the UK. I`m sure it`s all about budget constraints with our National Health Service already overstretched but I`m keeping my fingers crossed they come to a decision that will benefit as many people as possible.
Isiscat2011 said
Jun 17, 2014
It is all about the benjamins. We need global health care policies where life saving drugs are at stake. I don't know how anyone can still think what humanity is doing now is working.
Unless one consider mass suffering and population control through disease "working" but that is just wrong.
(Reuters) - Britain's healthcare cost-effectiveness watchdog NICE said on Monday it needed more information about Gilead Sciences' pricey new hepatitis C drug Sovaldi before deciding if it should be used on the state health service.
The National Institute for Health and Care Excellence (NICE) said it was "minded not to recommend" the drug, which is also known as sofosbuvir. The decision poses a hurdle to its widespread adoption in Britain.
The available evidence shows that sofosbuvir is an effective treatment for chronic hepatitis C in certain patients," said Carole Longson, director of the NICE Centre for Health Technology Evaluation.
"However, evidence is lacking for some subgroups of patients with chronic hepatitis C, and there are also substantial uncertainties in the evidence base presented by the manufacturer."
Sovaldi is far more effective and better-tolerated than older treatments, but its high cost has provoked criticism from healthcare campaigners and insurers.
The U.S. price for a 12-week course of treatment with Sovaldi is $84,000, or $1,000 for each once-daily pill. The price in Britain has been set lower at around 35,000 pounds ($58,800). ($1 = 0.5956 British Pounds)
Well lets hope the new Abbie drug soon to be approved provides much more realistic pricing. They're never going to make their money back at those prices....Greedy bar stewards might learn something when we are all cured from a much cheaper regime or so I hope!
Thanks for that Lee, and I posted about it in the HCV News section recently...
http://hepcfriends.activeboard.com/t57845830/nice-uk-consults-on-draft-guidance-on-the-drug-sofosbuvir-so/
The decision hasn`t been finalised yet, it`s still in the consultation stage until 4th July, but it looks likely at the moment that Sovaldi will only be made available to people in the most needy categories over here in the UK. I`m sure it`s all about budget constraints with our National Health Service already overstretched but I`m keeping my fingers crossed they come to a decision that will benefit as many people as possible.
It is all about the benjamins. We need global health care policies where life saving drugs are at stake. I don't know how anyone can still think what humanity is doing now is working.
Unless one consider mass suffering and population control through disease "working" but that is just wrong.
http://www.reuters.com/article/2014/06/16/us-gilead-sciences-britain-idUSKBN0ER0VI20140616
UK cost agency not ready to back Gilead hepatitis C drug
LONDON Mon Jun 16, 2014 5:31am EDT
RELATED TOPICS
(Reuters) - Britain's healthcare cost-effectiveness watchdog NICE said on Monday it needed more information about Gilead Sciences' pricey new hepatitis C drug Sovaldi before deciding if it should be used on the state health service.
The National Institute for Health and Care Excellence (NICE) said it was "minded not to recommend" the drug, which is also known as sofosbuvir. The decision poses a hurdle to its widespread adoption in Britain.
The available evidence shows that sofosbuvir is an effective treatment for chronic hepatitis C in certain patients," said Carole Longson, director of the NICE Centre for Health Technology Evaluation.
"However, evidence is lacking for some subgroups of patients with chronic hepatitis C, and there are also substantial uncertainties in the evidence base presented by the manufacturer."
Sovaldi is far more effective and better-tolerated than older treatments, but its high cost has provoked criticism from healthcare campaigners and insurers.
The U.S. price for a 12-week course of treatment with Sovaldi is $84,000, or $1,000 for each once-daily pill. The price in Britain has been set lower at around 35,000 pounds ($58,800). ($1 = 0.5956 British Pounds)